Dossier assessment
Atezolizumab (NSCLC) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Atezolizumab (NSCLC) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Atezolizumab (NSCLC) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
First-line treatment of advanced non-small cell lung cancer in adult patients for whom platinum-based chemotherapy is not an option and whose tumours have no EGFR mutations or ALK translocations.
- Patients with PD-L1 expressions ≥ 50% on tumour cells: added benefit not proven.
- Patients with PD-L1 expressions < 50% on tumour cells: added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2025-03-20 A G-BA decision was published.
Project details
- Project no.
- A24-97
- Commission
- Commission awarded on 23.09.2024 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A24-97_en
Connected Projects
-
Dossier assessment
Atezolizumab (NSCLC) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (NSCLC; combination with nab-paclitaxel and carboplatin) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (NSCLC; combination with bevacizumab, carboplatin and paclitaxel) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (breast cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Status: Commission completed
-
Dossier assessment
Atezolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed